
A recent study assessed the real-world effectiveness of baricitinib, a drug targeting Janus Kinase 1 and 2, in treating moderate-to-severe alopecia areata (AA). Among 32 patients, 28 received 2mg/day for 24 weeks, with four increasing to 4mg due to slow progress. Significant hair restoration was observed, with a notable decrease in SALT values at weeks 12 and 24. After 24 weeks, 50% showed an IGA score improvement of ≥2 points from baseline, and 68.75% had scores below 2. The study concludes that baricitinib exhibits promising clinical efficacy and safety in treating refractory AA.
Like
Save
Share